Increased serum gamma-glutamyl-transpeptidase concentration is associated with nonalcoholic steatosis and not with cholestasis in patients with chronic hepatitis C

Journal of Gastroenterology and Hepatology (Australia)

Volumn 22, Issue 10, 2007, Pages 1621-1626

  Benini, Federica ^a   Pigozzi, Marie Graciella ^a   Baisini, Ornella ^a   Romanini, Laura ^b   Ahmed, Hafez ^c   Pozzi, Alessandro ^a   Ricci, Chiara ^a   Lanzini, Alberto ^a,d  

^a SPEDALI CIVILI   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d Spedali Civili   (Italy)

Author keywords

Gamma glutamyl transpeptidase; Hepatitis C; Serum bile acid; Steatosis

Indexed keywords

ANTIVIRUS AGENT; BILE ACID; GAMMA GLUTAMYLTRANSFERASE;

ADULT; ARTICLE; BILE ACID BLOOD LEVEL; CHOLESTASIS; CONTROLLED STUDY; FEMALE; GAS CHROMATOGRAPHY; HEPATITIS C; HUMAN; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; VIROLOGY;

EID: 34548531030     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2006.04733.x     Document Type: Article

References (55)

1. Goldberg DM. Structural, functional, and clinical aspects of gamma-glutamyltransferase. CRC Crit Rev. Clin. Lab. Sci. 1980 12 : 1 58.
2. Huseby NE. Multiple forms of serum gamma-glutamyltransferase. Association of the enzyme with lipoproteins. Clin. Chim. Acta 1982 124 : 103 12.
3. Whitfield JB, Pounder RE, Neale G, Moss DW. Serum-glutamyl transpeptidase activity in liver disease. Gut 1972 13 : 702 8.
4. Rollason JG, Pincherle G, Robinson D. Serum gamma glutamyl transpeptidase in relation to alcohol consumption. Clin. Chim. Acta 1972 39 : 75 80.
5. Rosalki SB, Rau D. Serum γ-glutamyl transpeptidase activity in alcoholism. Clin. Chim. Acta 1972 39 : 41 7.
6. Rosalki SB, Tarlow D, Rau D. Plasma gamma-glutamyl transpeptidase elevation in patients receiving enzyme-inducing drugs. Lancet 1971 2 : 376 7.
7. Whitfield JB, Moss DW, Neale G, Orme M, Breckenridge A. Changes in plasma γ-glutamyl transpeptidase activity associated with alterations in drug metabolism in man. Br. Med. J. 1973 1 : 316 18.
8. Itoh S, Nakajima M. Liver gamma-glutamyltransferase activity in viral liver disease. Digestion 1986 33 : 121 5.
9. Trauner M, Fickert P, Stauber RE. Inflammation-induced cholestasis. J. Gastroenterol. Hepatol. 1999 14 : 946 59.
10. Pigozzi G, Sorbara R, Baisini O et al. A controlled randomised trial of t-UDCA as adjuvant to interferon for treatment of chronic hepatitis C: an interferon sparing effect of t-UDCA. Hepatol. Res. 2002 23 : 227.
11. Baisini O, Gracielle Pigozzi M, Benini F et al. A randomised, open label, controlled trial on the effect of interferon plus amantadine compared with interferon alone for treatment of chronic hepatitis C. Hepatol. Res. 2003 26 : 167 73.
12. Ruttmann E, Brant LJ, Concin H, Diem G, Rapp K, Ulmer H. Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163 9 44 Austrian adults. Circulation 2005 112 : 2130 7.
13. Whitfield JB. Gamma glutamyl transferase. Crit Rev. Clin. Lab. Sci. 2001 38 : 263 355.
14. Whitfield JB, Zhu G, Nestler JE, Heath AC, Martin NG. Genetic covariation between serum gamma-glutamyltransferase activity and cardiovascular risk factors. Clin. Chem. 2002 48 : 1426 31.
15. Wannamethee G, Ebrahim S, Shaper AG. Gamma-glutamyltransferase: determinants and association with mortality from ischemic heart disease and all causes. Am. J. Epidemiol. 1995 142 : 699 708.
16. Bach N, Thung SN, Schaffner F. The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. Hepatology 1992 15 : 572 7.
17. Lefkowitch JH, Schiff ER, Davis GL et al. Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Therapy Group. Gastroenterology 1993 104 : 595 603.
18. Betro MG, Oon RC, Edwards JB. Gamma-glutamyl transpeptidase in diseases of the liver and bone. Am. J. Clin. Pathol. 1973 60 : 672 8.
19. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001 33 : 1358 64.
20. Fartoux L, Poujol-Robert A, Guechot J, Wendum D, Poupon R, Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005 54 : 1003 8.
21. Serfaty L, Giral P, Loria A, Andreani T, Legendre C, Poupon R. Factors predictive of the response to interferon in patients with chronic hepatitis C. J. Hepatol. 1994 21 : 12 17.
22. Hwang SJ, Luo JC, Lai CR et al. Clinical, virologic and pathologic significance of elevated serum gamma-glutamyl transpeptidase in patients with chronic hepatitis C. Zhonghua Yi Xue Za Zhi (Taipei) 2000 63 : 527 35.
23. Camma C, Giunta M, Chemello L et al. Chronic hepatitis C: interferon retreatment of relapsers. A meta-analysis of individual patient data. European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 1999 30 : 801 7.
24. Camma C, Bruno S, Schepis F et al. Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data. Gut 2002 51 : 864 9.
25. Battezzati PM, Podda M, Bruno S et al. Factors predicting early response to treatment with recombinant interferon alpha-2a in chronic non-A, non-B hepatitis. Preliminary report of a long-term trial. Ital. J. Gastroenterol. 1992 24 : 481 4.
26. Romero-Gomez MMV, Andrade RJ, Salmeron J et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005 128 : 636 41.
27. Ioannou GN, Weiss NS, Boyko EJ, Kahn SE, Lee SP. Contribution of metabolic factors to alanine aminotransferase activity in persons with other causes of liver disease. Gastroenterology 2005 128 : 627 35.
28. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am. J. Gastroenterol. 2003 98 : 960 7.
29. Verma A, Jazrawi RP, Ahmed HA et al. Optimum dose of ursodeoxycholic acid in primary biliary cirrhosis. Eur. J. Gastroenterol. Hepatol. 1999 11 : 1069 76.
30. Heuman DM. Quantitative estimation of the hydrophilic-hydrophobic balance of mixed bile salt solutions. J. Lipid Res. 1989 30 : 719 30.
31. Knodell RG, Ishak KG, Black WC et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981 1 : 431 5.
32. Trinchet JC, Gerhardt MF, Balkau BB, Munz C, Poupon RE. Serum bile acids and cholestasis in alcoholic hepatitis. Relationship with usual liver tests and histological features. J. Hepatol. 1994 21 : 235 40.
33. Hourigan LF, Macdonald GA, Purdie D et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999 29 : 1215 19.
34. Patton HM, Patel K, Behling C et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J. Hepatol. 2004 40 : 484 90.
35. Nakanishi N, Suzuki K, Tatara K. Serum gamma-glutamyltransferase and risk of metabolic syndrome and type 2 diabetes in middle-aged Japanese men. Diabetes Care 2004 27 : 1427 32.
36. Lee DH, Jacobs DR Gross M et al. Gamma-glutamyltransferase is a predictor of incident diabetes and hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Clin. Chem. 2003 49 : 1358 66.
37. Rantala AO, Lilja M, Kauma H, Savolainen MJ, Reunanen A, Kesaniemi YA. Gamma-glutamyl transpeptidase and the metabolic syndrome. J. Intern. Med. 2000 248 : 230 8.
38. Nakanishi N, Nishina K, Li W, Sato M, Suzuki K, Tatara K. Serum gamma-glutamyltransferase and development of impaired fasting glucose or type 2 diabetes in middle-aged Japanese men. J. Intern. Med. 2003 254 : 287 95.
39. Pompella A, Emdin M, Passino C, Paolicchi A. The significance of serum gamma-glutamyltransferase in cardiovascular diseases. Clin. Chem. Lab. Med. 2004 42 : 1085 91.
40. Conigrave KM, Saunders JB, Reznik RB, Whitfield JB. Prediction of alcohol-related harm by laboratory test results. Clin. Chem. 1993 39 : 2266 70.
41. Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM. Tumor necrosis factor alpha inhibits signaling from the insulin receptor. Proc. Natl. Acad. Sci. USA 1994 91 : 4854 8.
42. Shintani Y, Fujie H, Miyoshi H et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004 126 : 840 8.
43. Zekry A, McHutchison JG, Diehl AM. Insulin resistance and steatosis in hepatitis C virus infection. Gut 2005 54 : 903 6.
44. Marchesini G, Brizi M, Morselli-Labate AM et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am. J. Med. 1999 107 : 450 5.
45. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005 42 : 987 1000.
46. Moriya K, Yotsuyanagi H, Shintani Y et al. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J. Gen. Virol. 1997 78 : 1527 31.
47. Rubbia-Brandt L, Quadri R, Abid K et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J. Hepatol. 2000 33 : 106 15.
48. Kumar D, Farrell GC, Fung C, George J. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response. Hepatology 2002 36 : 1266 72.
49. Festi D, Morselli Labate AM, Roda A et al. Diagnostic effectiveness of serum bile acids in liver diseases as evaluated by multivariate statistical methods. Hepatology 1983 3 : 707 13.
50. Monroe PS, Baker AL, Schneider JF, Krager PS, Klein PD, Schoeller D. The aminopyrine breath test and serum bile acids reflect histologic severity in chronic hepatitis. Hepatology 1982 2 : 317 22.
51. Kishimoto Y, Hijiya S, Takeda I. Clinical significance of fasting serum bile acid in the long-term observation of chronic liver disease. Am. J. Gastroenterol. 1985 80 : 136 8.
52. Shima T, Tada H, Morimoto M et al. Serum total bile acid level as a sensitive indicator of hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment. J. Gastroenterol. Hepatol. 2000 15 : 294 9.
53. Vlahcevic ZR, Buhac I, Farrar JT, Bell CC Swell L. Bile acid metabolism in patients with cirrhosis. I. Kinetic aspects of cholic acid metabolism. Gastroenterology 1971 60 : 491 8.
54. Vlahcevic ZR, Juttijudata P, Bell CC Swell L. Bile acid metabolism in patients with cirrhosis. II. Cholic and chenodeoxycholic acid metabolism. Gastroenterology 1972 62 : 1174 81.
55. Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997 113 : 884 90.